• Arrowhead Pharmaceuticals recently delivered strong first quarter fiscal 2026 results that exceeded earnings and revenue expectations, while its Chief Medical Officer James C. Hamilton sold 10,000 shares on March 5, 2026 under a 10b5-1 trading plan, retaining direct ownership of 236,958 shares.
• Alongside the better-than-expected quarter, investors are closely watching Arrowhead’s Phase 3 plozasiran SHASTA3/4 trial, which analysts have identified as an important upcoming potential catalyst for the company.
• With first quarter results topping expectations, we’ll examine how this earnings momentum shapes Arrowhead’s investment narrative and upcoming plozasiran catalyst.

AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Arrowhead Pharmaceuticals Investment Narrative Recap

To own Arrowhead Pharmaceuticals, you need to believe its RNAi platform and late stage programs, especially plozasiran, can justify today’s premium valuation and heavy R&D spend. The strong Q1 fiscal 2026 beat supports the balance sheet ahead of key readouts, while the upcoming Phase 3 plozasiran SHASTA3/4 trial remains the key near term catalyst. The recent CMO share sale under a 10b5-1 plan does not appear to materially change the core risk that late stage data or regulatory outcomes could disappoint.

Against this backdrop, Arrowhead’s packed conference schedule in early March 2026, including TD Cowen and Barclays healthcare conferences, is particularly relevant. These events give management a platform to clarify how the better than expected earnings, plozasiran’s evolving profile, and broader cardiometabolic and obesity pipeline fit together in the story. Any updated color on capital needs, partner milestones, or trial timing from these appearances could influence how investors handicap the upcoming SHASTA3/4 catalyst.

Yet despite the strong quarter, investors should be aware that rising Phase 3 and commercialization costs could still force future capital raises that...

Arrowhead Pharmaceuticals’ narrative projects $398.8 million in revenue and $64.0 million in earnings by 2028.

Uncover how Arrowhead Pharmaceuticals' forecasts yield a $64.08 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming around US$523 million in 2028 revenue and US$74 million in earnings, which paints a far more upbeat picture than the consensus view and could shift again after this earnings beat and the risk of higher cash burn you have just read about.

Explore 3 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth less than half the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• Find 46 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.